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Quality of Care of the Initial Patient Cohort of the Diabetes
Collaborative Registry
Suzanne V. Arnold, MD, MHA; Abhinav Goyal, MD, MHS; Silvio E. Inzucchi, MD; Darren K. McGuire, MD, MHSc; Fengming Tang, MS;
Sanjeev N. Mehta, MD, MPH; Laurence S. Sperling, MD; Thomas M. Maddox, MD, MSc; Daniel Einhorn, MD; Nathan D. Wong, PhD;
Niklas Hammar, PhD; Peter Fenici, MD, PhD; Kamlesh Khunti, MD, PhD; Carolyn S. P. Lam, MBBS, PhD; Mikhail Kosiborod, MD
Background-—Although guidelines and performance measures exist for patients with diabetes mellitus, achievement of these
metrics is not well known. The Diabetes Collaborative Registry (DCR) was formed to understand the quality of diabetes mellitus
care across the primary and specialty care continuum in the United States.
Methods and Results-—We assessed the frequency of achievement of 7 diabetes mellitus–related quality metrics and variability
across the Diabetes Collaborative Registry sites. Among 574 972 patients with diabetes mellitus from 259 US practices, median
(interquartile range) achievement of the quality metrics across the practices was the following: (1) glycemic control: 19% (5–47); (2)
blood pressure control: 80% (67–88); (3) angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in patients with
coronary artery disease: 62% (51–69); (4) nephropathy screening: 62% (53–71); (5) eye examination: 0.7% (0.0–79); (6) foot
examination: 0.0% (0.0–2.3); and (7) tobacco screening/cessation counseling: 86% (80–94). In hierarchical, modiﬁed Poisson
regression models, there was substantial variability in meeting these metrics across sites, particularly with documentation of
glycemic control and eye and foot examinations. There was also notable variation across specialties, with endocrinology practices
performing better on glycemic control and diabetes mellitus foot examinations and cardiology practices succeeding more in blood
pressure control and use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers.
Conclusions-—The Diabetes Collaborative Registry was established to document and improve the quality of outpatient diabetes
mellitus care. While target achievement of some metrics of cardiovascular risk modiﬁcation was high, achievement of others was
suboptimal and highly variable. This may be attributable to fragmentation of care, lack of ownership among various specialists
concerning certain domains of care, incomplete documentation, true gaps in care, or a combination of these factors. ( J Am Heart
Assoc. 2017;6:e005999. DOI: 10.1161/JAHA.117.005999.)
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B ecause of population growth, aging, urbanization, obe-sity, and physical inactivity,1 the prevalence of type 2
diabetes mellitus continues to escalate globally.2 Diabetes
mellitus presently affects an estimated 30 million people in
the United States,3 with increases evident in every age group,
in both sexes, in every racial/ethnic group, by all education
levels, and in all income brackets.4 Despite signiﬁcant
advances in treatment and outcomes,5 the impact of diabetes
mellitus continues to be substantial on cardiovascular
complications, mortality,6 and resource use.7–10 In response
to the increasing prevalence and impact of diabetes mellitus,
evidence-based care guidelines11–14 and performance mea-
sures have been developed for the care of patients with
diabetes mellitus.15–17 However, mechanisms to evaluate
quality of care, to examine the variability in quality care
delivery both nationally and among specialties and sites, and
to highlight potential opportunities for quality improvement
have thus far been limited.
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The Diabetes Collaborative Registry (DCR) is a real-world,
quality-oriented registry covering the spectrum from primary
to specialty outpatient care in the United States, thereby
permitting evaluations of multidisciplinary diabetes mellitus
care across the disease process (from diagnosis to compli-
cations) and the relationship between treatment patterns and
health outcomes. The DCR was developed, in part, to
understand the quality of care delivered to patients with
diabetes mellitus and adherence to practice guidelines and
performance measures. If substantial deﬁciencies are noted in
achievement of particular measures, this could highlight
opportunities for quality improvement efforts within the DCR,
with the ultimate goal of improving care and outcomes.
However, to understand where efforts should be focused, we
must ﬁrst document the current state of care and understand




The DCR was launched in 2014 as a collaborative effort by the
American College of Cardiology, American Diabetes Associ-
ation, American College of Physicians, American Association
of Clinical Endocrinologists, and Joslin Diabetes Center.18 The
DCR is a prospective, ofﬁce-based, quality-oriented registry of
patients with diabetes mellitus, covering the spectrum from
primary to specialty outpatient care in the United States.
Primary care, endocrinology, multispecialty, and cardiology
practices are invited to participate in DCR through a public
website (www.thediabetesregistry.org) and through partnering
societies. Cardiology and multispecialty practices currently in
the American College of Cardiology–National Cardiovascular
Data Registry PINNACLE program were targeted as initial sites
for DCR because of existing information technology platforms.
Within participating practices, patient data are collected
through an automated system integration solution that
periodically extracts relevant data elements from electronic
health records (EHRs). All protected health information is de-
identiﬁed at the time of data extraction and stored in a secure
facility, in a manner compliant with Health Insurance Porta-
bility and Accountability Act regulations. Data collection is
standardized using established deﬁnitions, uniform data entry
and transmission, and quality checks. In addition, rigorous
back-end data quality checks are performed on the extracted
data, and any data not meeting predeﬁned statistical or
clinical plausibility thresholds are quarantined from analyses
and ﬂagged for manual review and follow-up with individual
practices. Because registry participation requires no data
collection beyond that of the routine clinical care, and
because of the de-identiﬁed nature of the collected informa-
tion, waiver of written informed consent and authorization for
this study was granted by Chesapeake Research Review
Incorporated. For patients with more than 1 clinic visit during
the monitoring period, the most recent visit was used for
analysis.
Selection of Quality Metrics
Diabetes mellitus quality metrics that were selected to be
tracked in DCR (Table 1) include 7 metrics established by the
American College of Cardiology/American Heart Association
Task Force on Performance Measures19–21 and the Centers
for Medicare and Medicaid Services Physician Quality Report-
ing System22: glycemic control (hemoglobin A1c checked in
past year and documented to be ≤9%), blood pressure control
(hypertension and blood pressure <140/90 or on ≥2 antihy-
pertensive medications), angiotensin-converting enzyme inhi-
bitor (ACE-I) or angiotensin II receptor blocker (ARB) for
patients with coronary artery disease, nephropathy screening,
diabetes mellitus eye examination, diabetes mellitus foot
examination, and tobacco screening and cessation counseling
(screened for tobacco and, if a current user, given cessation
counseling). For each of the metrics, DCR worked with the
individual practice and EHR provider to determine the best
mechanisms to map the EHR data to determine whether the
Clinical Perspective
What Is New?
• We assessed the frequency of achievement of diabetes
mellitus–related quality metrics in routine clinical practice
and found this to be suboptimal for many of the metrics.
• There was substantial variation in achieving these metrics
across both individual sites and across specialties, with
specialties having higher achievement of metrics that are
more associated with that specialty (eg, endocrinology
practices do better at documenting diabetes mellitus foot
examinations while cardiology practices control blood
pressure better).
What Are the Clinical Implications?
• Achieving quality care in patients with diabetes mellitus
requires integration of multiple specialties, which has been
hindered by a lack of communication across electronic
systems.
• All specialties need to take a greater role in ensuring that
critical aspects of diabetes mellitus care are addressed by
the care team instead of simply focusing on a deﬁned sliver
of clinical care.
• Systems-based approaches are also needed to optimize
team-based care, such as an integrated diabetes mellitus
care center, to improve the care of these complex patients.
DOI: 10.1161/JAHA.117.005999 Journal of the American Heart Association 2






















metrics are being met, which included a combination of
discrete data ﬁelds, billing data, and physician notes.
Statistical Analyses
Demographics, comorbidities, laboratory values, and selected
medications were reported for the study cohort as percent-
ages (categorical variables) or means (SDs [continuous
variables]). We ﬁrst examined the average achievement of
each metric across all eligible patients in DCR. We then
calculated the percentage of patients who met criteria for
each of the DCR performance metrics at the practice level.
Sites with <10 patients eligible for a metric were excluded
from analysis for that metric. We examined the median site-
level achievement of each of the quality metrics, plotted the
raw rates of adherence across sites, and compared the
median rates among primary care physicians, endocrinolo-
gists, and cardiologists using v2 tests. For each quality metric,
we also explored site-level variability with hierarchical Poisson
models predicting achievement of each metric, with site
included as a random effect. Variability among sites was
quantiﬁed using the median rate ratio,23 which estimates the
average difference in rates of 2 hypothetical patients
achieving the metric if they presented to 2 random sites in
the data set. By deﬁnition, all median rate ratios are >1, and a
median rate ratio >1.2 is generally accepted as indicating
signiﬁcant variability. To examine whether certain sites met
quality metrics in multiple areas, we calculated for each site
the number of metrics for which the site was in the upper
quartile of performance.
To examine the difference in rates of achievement of each
metric by specialty, geography, practice specialty, and (for the
metrics that included a monitoring period) the number of
visits during the monitoring period were then added as ﬁxed
effects in the models, with rate ratios calculated for each
specialty (with cardiology as the reference). All analyses were
performed with SAS version 9.4 (SAS Institute, Cary, NC), R
version 3.2.0 (Foundation for Statistical Computing, Vienna,




We assessed clinical data from 575 046 patients with
diabetes mellitus enrolled in DCR from 272 US practices
between 2015 and 2016. We excluded 13 practices that
enrolled fewer than 10 patients (total of 74 patients), making
our ﬁnal study sample 574 972 patients from 259 US
practices across 3086 providers in 39 states. Of these initial
sites in DCR, 146 (56.4%) were primary care practices, 93
(35.9%) were cardiology practices, and 20 (7.7%) were
endocrinology practices. Table 2 shows the baseline charac-
teristics of the patients in the study cohort. Mean age was
65.9 years, 50.5% were male, and 83.3% were white race.
Cardiac risk factors and conditions were common, with 76.3%
having hypertension, 36.3% with known coronary artery
disease, 14.3% with chronic heart failure, and 15.1% with
peripheral artery disease. Oral glucose-lowering medications
were prescribed to 52.0% of patients, and 20.4% were on
insulin.
Achievement of Quality Metrics and Site-Level
Variability
Analyzing patient-level data across the 574 972 patients in
DCR, the number of patients eligible for each of the 7 quality
Table 1. Quality Metrics in the DCR
Metric Name
Time Frame for
Assessment Details of Metric
Glycemic control 1 y Patients ≤75 y with diabetes mellitus who had hemoglobin A1c checked and ≤9.0%
Blood pressure control Most recent visit Patients with hypertension who have a blood pressure <140/90 mm Hg or who have a blood
pressure ≥140/90 mm Hg and were prescribed ≥2 antihypertensive medications
ACE-I or ARB with coronary
artery disease
Most recent visit Patients with coronary artery disease who were prescribed ACE-I or ARB
Diabetes mellitus: medical
attention for nephropathy
1 y Patients ≤75 y with diabetes mellitus who had a nephropathy screening test (serum creatinine or
urinary protein) or evidence of nephropathy
Diabetes mellitus eye exam 1 y Patients who received an eye exam
Diabetes mellitus foot exam 1 y Patients who received a foot exam
Tobacco use: screening and
cessation intervention
2 y Patients who were screened for tobacco use and, if identified as a tobacco user, received
cessation counseling
For all metrics except blood pressure and ACE-I/ARB, if the patient met the metric at any visit during the time frame for assessment (eg, 1 y from the last clinic visit in DCR), then the
metric was considered to be met. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; DCR, Diabetes Collaborative Registry.
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metrics and the proportion of eligible patients meeting those
metrics are shown in Table 3. Across all eligible patients, the
metrics with the highest achievement were documentation of
blood pressure control and tobacco screening and cessation
counseling (81.8% and 86.3%, respectively) and the lowest
was documentation of diabetes mellitus foot examination at
14.8%. After calculating achievement of each metric at the
site level and examining these rates across the 259 practices,
the median (interquartile range) achievement was as follows:
(1) glycemic control: 19.3% (5.0–47%); (2) blood pressure
control: 79.8% (66.9–87.5%); (3) ACE-I or ARB with coronary
artery disease: 62.4% (50.9–69.0%); (4) nephropathy screen-
ing: 61.5% (53.4–71.4%); (5) diabetes mellitus eye examina-
tion: 0.7% (0.0–78.5%); (6) diabetes mellitus foot examination:
0.0% (0.0–2.3%); and (7) tobacco screening and cessation
counseling: 86.4% (80.0–93.5%) (Table 4). The variability in
meeting the metrics across sites is shown in Figure 1. There
was only modest variability in sites meeting the metrics for
ACE-I/ARB for coronary artery disease, nephropathy screen-
ing, tobacco screening and cessation counseling, and blood
pressure control, with median rate ratios of 1.29, 1.23, 1.25,
and 1.22, respectively. The most variability was evident in
glycemic control and in performing diabetes mellitus eye and
foot examinations, where many sites did not have any
patients meeting these measures but some sites achieved
them on nearly all patients. The median rate ratios for these
metrics were 4.28, 27.49, and 17.72, respectively. This
indicates, for example, that a patient could be 27 times more
likely to get a diabetes mellitus eye examination if he or she
went to 1 random site versus another site. When examining
the number of metrics for which each site was a good
performer (in the upper quartile for the metric), the majority of
sites met only a few metrics (Figure 2). Only 17% of sites were
high performers for 4 or more of the quality metrics.
Achievement of Quality Metrics Across
Specialties
The median rates of achievement of the quality metrics
according to practice specialty are shown in Table 5.
Table 2. Baseline Characteristics of Analytic Cohort
All Patients (n=574 972) Cardiology (n=278 110) Endocrine (n=95 406) Primary Care (n=201 456)
Age, y 65.913.6 67.412.6 63.714.7 64.714.1
Male sex 50.5% 54.1% 48.20% 46.6%
White race 83.3% 85.6% 85.10% 79.3%
Hemoglobin A1c, % 7.11.8 7.42.0 6.91.5 7.01.9
Diabetes mellitus type II 96.0% 95.4% 95.4% 97.0%
On oral glucose-lowering medications 52.0% 59.1% 38.7% 48.4%
On insulin 20.4% 23.9% 14.0% 18.7%
Hypertension 76.3% 86.7% 72.8% 63.9%
Systolic blood pressure, mm Hg 130.517.8 130.718.4 129.116.0 131.017.6
Diastolic blood pressure, mm Hg 74.510.8 73.710.9 75.79.9 75.210.9
Dyslipidemia 70.7% 80.0% 74.0% 56.6%
Coronary artery disease 36.3% 57.6% 19.8% 14.9%
Prior myocardial infarction 7.8% 13.2% 2.1% 3.0%
Prior coronary bypass graft surgery 7.2% 13.3% 1.9% 1.6%
Heart failure 14.3% 21.8% 6.9% 7.4%
Peripheral arterial disease 15.1% 17.8% 12.9% 12.3%
Prior stroke 11.3% 15.1% 10.8% 6.1%
Atrial fibrillation/flutter 14.4% 22.8% 8.7% 5.6%
Chronic kidney disease 14.2% 9.7% 10.6% 22.0%
Tobacco use
Never 53.8% 49.4% 58.2% 58.0%
Current 13.9% 13.8% 13.8% 14.2%
Former 32.3% 36.8% 27.9% 27.8%
All comparisons of patients among specialties were signiﬁcant at P<0.001.
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Endocrinology practices had higher rates of achievement of
documentation of glycemic control, diabetes mellitus eye
examinations, and diabetes mellitus foot examinations. Car-
diology practices had the highest achievement of blood
pressure control, ACE-I/ARB among patients with coronary
artery disease, and nephropathy screening. In the hierarchical,
modiﬁed Poisson models that also adjusted for geographical
region, physician specialty was signiﬁcantly associated with
achievement of all of the quality metrics except for diabetes
mellitus eye examinations, which did not vary signiﬁcantly
among practices (Table 5). Most of these differences were
statistically signiﬁcant but clinically small (rate ratios 0.8–
1.1). However, achievement of glycemic control and diabetes
mellitus foot examinations did vary substantially among
specialties. Patients seen in endocrinology and primary care
ofﬁces were 3.77 times (95% CI 2.04–6.96) and 2.18 times
(95% CI 1.43–3.31), respectively, more likely to achieve
documentation of glycemic control as compared with those
seen in cardiology practices (P<0.001). Patients seen in
endocrinology and primary care ofﬁces were 9.32 times (95%
CI 1.75–49.50) and 3.97 times (95% CI 1.74–9.05), respec-
tively, more likely to have a diabetes mellitus foot examination
documented as compared with those seen in cardiology
practices (P=0.001).
Discussion
In a real-world cohort of >500 000 patients with diabetes
mellitus across 259 US practices and 3086 cardiologists,
endocrinologists, and primary care physicians, we found
substantial variability in documented achievement of quality
metrics across individual practices and among the 3 practice
specialties. Achievement of some metrics was high, namely,
blood pressure control and tobacco screening/cessation
counseling, with median rates across the practices of >75%.
Documentation of glycemic control and diabetes mellitus eye
and foot examinations occurred much less frequently with
marked variability across sites and across practice
Table 3. Performance on Quality Metrics (All Patients in DCR)
Quality Metric Eligible for Metric* Met Metric
Glycemic control† 428 804 out of 569 626 (75.3%) 139 423 out of 428 804 (32.2%)
Blood pressure control 426 879 out of 528 519 (80.8%) 349 391 out of 426 879 (81.8%)
ACE-I out of ARB with coronary artery disease 198 892 out of 535 861 (37.1%) 133 743 out of 198 892 (67.2%)
Nephropathy screening 439 546 out of 574 941 (76.5%) 289 679 out of 439 546 (65.9%)
Diabetes mellitus eye exam 439 571 out of 574 972 (76.5%) 215 004 out of 439 571 (48.9%)
Diabetes mellitus foot exam 573 670 out of 574 972 (99.8%) 84 698 out of 573 670 (14.8%)
Tobacco screening and cessation counseling‡ 563 452 out of 564 677 (99.8%) 486 167 out of 563 452 (86.3%)
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; DCR, Diabetes Collaborative Registry; HbA1c, hemoglobin A1c.
*Denominators for eligibility differ since some data from particular practices were excluded because of inconsistencies in data or small numbers of eligible patients per practice.
†Not meeting the metric of documentation of glycemic control was because of a lack of HbA1c checked in the past year in 62.6% and HbA1c >9% in 4.8%.
‡Not meeting the metric of documentation of tobacco screening was because of lack of screening for tobacco in 7.1% and not providing cessation counseling to current smokers in 6.6%
(48.4% of current smokers were provided cessation counseling).
Table 4. Performance on Quality Metrics Across Sites
Quality Metric
Median Rate of Meeting
Metric Across Sites (IQR) Range Median Rate Ratio*
Glycemic control 19.3% (5.0–47.0) 0.0 to 89.0 4.28 (3.77–4.99)
Blood pressure control 79.8% (66.9–87.5) 12.0 to 100.0 1.22 (1.20–1.25)
ACE-I/ARB with coronary artery disease 62.4% (50.9–69.0) 5.6 to 100.0 1.29 (1.25–1.33)
Nephropathy screening 61.5% (53.4–71.4) 5.3 to 92.0 1.23 (1.21–1.26)
Diabetes mellitus eye exam 0.7% (0.0–78.5) 0.0 to 100.0 27.49 (20.39–39.58)
Diabetes mellitus foot exam 0.0% (0.0–2.3) 0.0 to 97.0 17.72 (13.62–24.47)
Tobacco screening and cessation counseling 86.4% (80.0–93.5) 0.9 to 100.0 1.25 (1.23–1.29)
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; IQR, interquartile range.
*The median rate ratio estimates the average difference in rates of achieving the metric of 2 hypothetical patients if they presented to 2 random sites in the data set. By deﬁnition, all
median rate ratios are >1 and ratios >1.2 are generally accepted as indicating signiﬁcant variability.
DOI: 10.1161/JAHA.117.005999 Journal of the American Heart Association 5























































































































































































































Figure 1. Variability of achievement of quality metrics across sites. A, HbA1c checked and ≤9% (n=241). B, HbA1c ≤9%, if
checked (n=241). C, Blood pressure control (n=244). D, ACE-I or ARB with CAD (n=233). E, Nephropathy screening (n=258). F,
Diabetes mellitus eye examination (n=259). G, Diabetes mellitus foot examination (n=259). H, Tobacco screening and counseling
(n=258). ACE-I indicates angiotensin-converting enzyme-inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; CAD,
coronary artery disease; DM, diabetes mellitus; HbA1c, hemoglobin A1c.
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specialties. Not surprisingly, endocrinology practices had
better achievement of the metrics of documented glycemic
control and diabetes mellitus eye and foot examinations,
whereas cardiology practices were most successful at doc-
umented blood pressure control, nephropathy screening, and
use of ACE-I or ARBs in patients with concomitant coronary
disease. While it is difﬁcult to determine speciﬁc reasons for
differences in achievement of these quality metrics, this is
likely a combination of a lack of or inadequate documentation
(eg, most deﬁciencies in glycemic control were because of
lack of documentation of hemoglobin A1c level in the past
year and not because of poor control, when measured),
fragmentation of care, ownership of issues (eg, cardiologists
not feeling responsible for certain aspects of diabetes mellitus
care), and possibly true gaps in care.
Despite guidelines and standards of care for treating
patients with diabetes mellitus,2,12,14,24,25 the practical appli-
cation of these evidence-based recommendations has been
suboptimal.26 The DCR was developed to document the
current quality of care among patients with diabetes mellitus
across the spectrum of primary and specialty care. Through
collection of data on a national level from providers involved
in all phases of diabetes mellitus care and feedback of these
data to the practices, we are hopeful that these data will spur
improvement of care over time. In this study documenting the
initial achievement of the quality metrics, we have identiﬁed a
number of possible gaps in care. EHRs were designed to
improve communication across providers, increase individual
provider’s ability to manage chronic diseases, and, in turn,
improve the quality of medical care. However, the change in
quality care has been suboptimal, in part because of use of
EHRs simply as a means of documentation, as opposed to
management of care. Furthermore, the lack of communication
across systems prevents true integration of care, which is of
critical importance when dealing with a chronic disease, such
as diabetes mellitus, which requires involvement by multiple
specialties for optimal management.
Some of the gaps in care that we identiﬁed may be simply
because of lack of documentation and not a deﬁciency of care
(eg, eye examination was done by primary care but not
documented in cardiology record). Although it is unclear as to
who “owns” particular aspects of care, a cardiologist would
likely not feel responsible for—nor perhaps feel qualiﬁed to
perform—a diabetes mellitus eye or foot examination.
However, given the intersection of diabetes mellitus and
cardiovascular health and the complex effects of diabetes
mellitus medications on cardiovascular outcomes, the overall
care of these patients will likely become increasingly
integrated over time, with all specialties needing to take a
greater role in ensuring that critical aspects of diabetes
mellitus care are addressed by the care team. These data also























# of Metrics in Upper Quartile of Performance
Figure 2. Number of metrics for which each site is in the upper
quartile of performance.
Table 5. Performance on Quality Metrics Across Specialties
Quality Metric
Cardiology (n=93)* Endocrinology (n=20)* Primary Care (n=146)*
P Value for
Specialty in ModelMedian† (IQR) Median† (IQR) Rate Ratio‡ (95% CI) Median† (IQR) Rate Ratio‡ (95% CI)
Glycemic control 9.5% (2.3–30.7) 53.1% (18.9–68.2) 3.77 (2.04–6.96) 27.5% (7.2–54.9) 2.18 (1.43–3.31) <0.001
Blood pressure control 87.3% (77.1–90.9) 76.9% (59.0–82.2) 0.84 (0.73–0.95) 76.9% (64.6–83.8) 0.90 (0.85–0.95) <0.001
ACE-I/ARB with CAD 66.6% (58.9–74.6) 59.0% (45.7–64.7) 0.79 (0.64–0.98) 58.1% (47.7–68.2) 0.86 (0.80–0.93) <0.001
Nephropathy screening 68.3% (59.0–74.4) 57.1% (51.5–65.6) 0.85 (0.79–0.92) 58.4% (50.1–64.3) 0.80 (0.76–0.85) <0.001
Diabetes mellitus eye exam 1.6% (0.0–57.3) 6.1% (0.0–80.1) 0.95 (0.15–6.07) 0.0% (0.0–83.2) 0.84 (0.32–2.19) 0.935
Diabetes mellitus foot exam 0.0% (0.0–0.9) 13.5% (0.0–50.3) 9.32 (1.75–49.50) 0.0% (0.0–12.6) 3.97 (1.74–9.05) 0.001
Tobacco screening and
cessation counseling
87.6% (79.3–93.5) 86.3% (82.8–90.9) 1.02 (0.96–1.08) 85.4% (76.9–93.3) 0.93 (0.88–1.00) 0.073
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; IQR, interquartile range.
*N represents the number of sites.
†Median rate of adherence at the practice level.
‡Cardiology practices as reference.
DOI: 10.1161/JAHA.117.005999 Journal of the American Heart Association 7






















approaches to optimize team-based care, such as an
integrated diabetes mellitus care center, and importantly,
the clear documentation of achievement of quality metrics
through easily retrievable electronic means. In addition, more
intensive use of EHRs with structured notes, disease
management, and clinical support tools may also be key
ways to improve the care of these complex patients.27
There have been several prior studies examining quality of
care of patients with diabetes mellitus, which have generally
been focused on goal attainment of cardiovascular risk factors
(eg, cholesterol, hemoglobin A1c, blood pressure, and body
mass index).28–32 For example, an analysis of the National
Health and Nutrition Examination Survey survey of patients
with self-reported diabetes mellitus showed that 87% of
patients had a hemoglobin A1c <9%, 73% and 71% reported
having an eye and foot examination in the prior year,
respectively, and 72% reported having a blood pressure
<140/90.31 These results were similar in integrated health-
care systems with less fragmentation of care, with data from
Kaiser Permanente in 2014 showing 82% of patients with
hemoglobin A1c <9%, 75% having a diabetes mellitus eye
examination, 96% with nephropathy screening, and 85% with a
blood pressure <140/90.33 While our quality metrics are
different from many of these goal-based measures, the
disconnect between our results and prior analyses highlight
the fractured care that patients with diabetes mellitus often
receive. Prior studies either used the patient as the subject of
assessment or came from integrated care systems. In
contrast, when we examined over 500 000 physician records
of patients with diabetes mellitus, documentation of many
aspects of diabetes mellitus care were suboptimal. While
some of these aspects of care may not be the “responsibility
of” the particular physician treating that patient (eg, cardiol-
ogists and diabetes mellitus foot and eye examinations), other
aspects (eg, glycemic control) likely should be more co-
managed. The DCR will be an important part in this integration
of care across the specialties and should promote more active
co-management of these complicated patients.
There are a number of potential limitations to our study
that merit further discussion. First, the selection of diabetes
mellitus quality metrics to be assessed in DCR could be
debated. The Steering Committee of DCR selected the
measures from those approved by the American College of
Cardiology/American Heart Association Task Force on Per-
formance Measures19–21 and based on the existing Centers
for Medicare and Medicaid Services Physician Quality Report-
ing System.22 Second, other quality metrics are intended to
be measured in DCR (eg, counseling on diet and exercise,
high-intensity statin use in patients with coronary or periph-
eral artery disease) but could not be assessed because of
current data limitations. We expect that additional registry
enhancements will allow these measures to be tracked in the
future. Third, because of the established mapping infrastruc-
ture with cardiology sites already participating in the
PINNACLE registry, there was a predominance of cardiology
practices in our initial analytic sample and only a small
minority of endocrinology practices. We were able to identify
some key practice patterns across the different specialties;
however, these analyses will become more robust as the
proportion of noncardiology practices increases in DCR.
In conclusion, the initial examination of cardiology,
endocrinology, and primary care practices in the DCR
demonstrated substantial variability in achievement of dia-
betes mellitus quality metrics. These data highlight important
potential gaps in care, which are likely multifactorial (docu-
mentation, fragmentation of care, ownership issues). Further
work is needed to integrate diabetes mellitus care across
primary and specialty care so as to minimize any true gaps in
care. The DCR is uniquely positioned to facilitate this process
and will hopefully result in improvement in the quality of care
and, ultimately, the outcomes of patients with diabetes
mellitus.
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